Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Generic medicines

Actavis accused of overcharging NHS for hydrocortisone tablets

The Competition and Markets Authority (CMA) has accused pharmaceutical company Actavis UK of breaking competition law by charging the NHS excessive prices for hydrocortisone tablets.

Actavis UK (formerly Auden Mckenzie) increased the price of 10mg hydrocortisone tablets by over 12,000% compared to the branded version of the drug, which was sold by a different company prior to April 2008. The amount the NHS was charged for 10mg packs of the drug rose from £0.70 in April 2008 to £88.00 per pack by March 2016.

Actavis UK also increased the price of 20mg hydrocortisone tablets by nearly 9,500%, charging the NHS £102.74 per pack by March 2016, up from £1.07 per pack.

Debranded (generic) drugs are not subject to price regulation.

Andrew Groves, the senior responsible officer at the CMA, the UK competition watchdog, said: “This is a lifesaving drug relied on by thousands of patients, which the NHS has no choice but to continue purchasing. We allege that the company has taken advantage of this situation and the removal of the drug from price regulation, leaving the NHS – and ultimately the taxpayer – footing the bill for the substantial price rises.”

Hydrocortisone tablets are used as the primary replacement therapy for patients with adrenal insufficiency, such as Addison’s disease. Around 943,000 packets of hydrocortisone tablets were dispensed in the UK in 2015.

Prior to April 2008, the NHS spent about £522,000 a year on hydrocortisone tablets, but in 2015 it spent £70m.

This month, the CMA fined Pfizer and Flynn Pharma a total of nearly £90m for charging excessive prices for the anti-epilepsy drug phenytoin sodium, after that drug was also debranded. In February 2016, it fined several pharmaceutical companies a total of £45m for anti-competitive agreements and conduct in relation to the supply of the antidepressant drug paroxetine. The CMA has three other ongoing investigations into the pharmaceutical sector.

Meanwhile, US authorities have accused six pharmaceutical firms from the US, India and Australia of price fixing by conspiring to raise the price of the antibiotic doxycycline and diabetes drug glyburide.

A civil lawsuit has been filed in 20 US states. Mylan, Heritage Pharmaceuticals, Teva Pharmaceutical USA and Citron Pharma, Aurobindo Pharma and Australia’s Mayne Pharmaceuticals are named in the lawsuit. Criminal charges have been brought against two former executives at Heritage.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20202106

Readers' comments (2)

  • Overall, the generics market works well, many generic drugs are much cheaper than their historic branded counterpart. But there are certain examples of generic medications where the market has failed. It certainly looks like some price fixing is taking place and we wouldn't accept this in any other market, why should healthcare be different? The government should step in and deal with this strongly , this would send a signal to other generics companies that seeks to profit in this way.

    Unsuitable or offensive? Report this comment

  • Everyone has forgotten how the banks crashed the economy back in 2008, the papers now tell us it was the immigrants, students the welfare state, anyone except those same banks. Similarly, the NHS is being ripped off by global pharmaceutical companies, yet our attention seems to be always directed towards the Doctors, Pharmacists and Nurses, the papers are trying their damnedest to blame them for all the NHS's ills.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Actavis Biologics Ltd, Estuary Banks, Liverpool

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.